Fetal hydantoin syndrome, also called fetal dilantin syndrome, is a group of defects caused to the developing fetus by exposure to teratogenic effects of phenytoin. Dilantin is the brand name of the drug phenytoin sodium in the United States, commonly used in the treatment of epilepsy.
It may also be called congenital hydantoin syndrome,[1] fetal hydantoin syndrome, dilantin embryopathy, or phenytoin embryopathy.
Association with EPHX1 has been suggested.[2] About one third of children whose mothers are taking this drug during pregnancy typically have intrauterine growth restriction with a small head and develop minor dysmorphic craniofacial features (microcephaly and intellectual disability) and limb defects including hypoplastic nails and distal phalanges (birth defects). Heart defects including ventricular septal defect, atrial septal defect, patent ductus arteriosus and coarctation of the aorta may occur in these children. A smaller population will have growth problems and developmental delay, or intellectual disability.
Heart defects and cleft lip[3] may also be featured.
There is no diagnostic testing that can identify fetal hydantoin syndrome. A diagnosis is made clinically based upon identification of characteristic symptoms in an affected infant in conjunction with a history of phenytoin exposure during gestation. It is important to note that the majority of infants born to women who take phenytoin during pregnancy will not develop fetal hydantoin syndrome.[4] The treatment of fetal hydantoin syndrome is directed toward the specific symptoms that are apparent in each individual. Treatment may require the coordinated efforts of a team of specialists. Pediatricians, oral surgeons, plastic surgeons, neurologists, psychologists, and other healthcare professionals may need to systematically and comprehensively plan an affected child's treatment. Infants with fetal hydantoin syndrome can benefit from early developmental intervention to ensure that affected children reach their potential. Affected children may benefit from occupational, physical and speech therapy. Various methods of rehabilitative and behavioral therapy may be beneficial. Additional medical, social and/or vocational services may be necessary. Psychosocial support for the entire family is essential as well.[4] When cleft lip and/or palate are present, the coordinated efforts of a team of specialists may be used to plan an affected child's treatment and rehabilitation. Cleft lip may be surgically corrected. Generally surgeons repair the lip when the child is still an infant. A second surgery is sometimes necessary for cosmetic purposes when the child is older. Cleft palate may be repaired by surgery or covered by an artificial device (prosthesis) that closes or blocks the opening. Surgical repair can be carried out in stages or in a single operation, according to the nature and severity of the defect. The first palate surgery is usually scheduled during the toddler period.[4]
1. Ridsdale L, Charlton J, Ashworth M, Richardson MP, Gulliford MC. Epilepsy mortality and risk factors for death in epilepsy: a population‐based study. Br J Gen Pract. 2011;61:e271–e278. [PMC free article] [PubMed] [Google Scholar] 2. Nicholas JM, Ridsdale L, Richardson MP, Ashworth M, Gulliford MC. Trends in antiepileptic drug utilisation in UK primary care 1993–2008: Cohort study using the General Practice Research Database. Seizure. 2012;21:466–70. [PubMed] [Google Scholar] 3. Briggs G, Freeman R, Yaffe S. Drugs in pregnancy and lactation. Philadelphia: Lippincott Williams & Wilkins; 2011. [Google Scholar] 4. Van Lang QN, Tassinari MS, Keith DA, Holmes LB. Effect of in utero exposure to anticonvulsants on craniofacial development and growth. J Craniofac Genet Dev Biol. 1984;4:115–33. [PubMed] [Google Scholar] 5. Webster WS, Howe AM, Abela D, Oakes DJ. The relationship between cleft lip, maxillary hypoplasia, hypoxia and phenytoin. Curr Pharm Des. 2006;12:1431–48. [PubMed] [Google Scholar] 6. Reed SC. An embryological study of harelip in mice. Anat Rec (Hoboken). 1933;56:101–10. [Google Scholar] 7. Diewert VM, Shiota K. Morphological observations in normal primary palate and cleft‐lip embryos in the Kyoto collection. Teratology. 1990;41:663–77. [PubMed] [Google Scholar] 8. Hiilesmaa VK, Teramo K, Granstrom ML, Bardy AH. Serum folate concentrations during pregnancy in women with epilepsy: relation to antiepileptic drug concentrations, number of seizures, and fetal outcome. Br Med J (Clin Res Ed). 1983;287:577–9. [PMC free article] [PubMed] [Google Scholar] 9. Azarbayjani F, Danielsson BR. Phenytoin‐induced cleft palate: evidence for embryonic cardiac bradyarrhythmia due to inhibition of delayed rectifier K+ channels resulting in hypoxia‐reoxygenation damage. Teratology. 2001;63:152–60. [PubMed] [Google Scholar] 10. Wells PG, Zubovits JT, Wong ST, Molinari LM, Ali S. Modulation of phenytoin teratogenicity and embryonic covalent binding by acetylsalicylic acid, caffeic acid, and alpha‐phenyl‐N‐t‐butylnitrone: implications for bioactivation by prostaglandin synthetase. Toxicol Appl Pharmacol. 1989;97:192–202. [PubMed] [Google Scholar] 11. Danielsson B, Sköld A‐C, Azarbayjani F, Öhman I, Webster W. Pharmacokinetic data support pharmacologically induced embryonic dysrhythmia as explanation to Fetal Hydantoin Syndrome in rats. Toxicol Appl Pharmacol. 2000;163:164–75. [PubMed] [Google Scholar] 12. Zhao Z, Reece EA. New concepts in diabetic embryopathy. Clin Lab Med. 2013;33:207–33. [PMC free article] [PubMed] [Google Scholar] 13. Qi H, Newman GC. Phenytoin‐induced hyperglycaemia may confound rat cerebroprotection models. Clin Exp Pharmacol Physio. 1996;23:893–7. [PubMed] [Google Scholar] 14. Kubow S. Inhibition of phenytoin bioactivation and teratogenicity by dietary N‐3 fatty‐acids in mice. Lipids. 1992;27:721–8. [PubMed] [Google Scholar] 15. Winn LM, Wells PG. Maternal administration of superoxide dismutase and catalase in phenytoin teratogenicity. Free Radic Biol Med. 1999;26:266–74. [PubMed] [Google Scholar] 16. Finnell RH, Bennett GD, Mather GG, Wlodarczyk B, Bajpai M, Levy RH. Effect of stiripentol dose on phenytoin‐induced teratogenesis in a mouse model. Reprod Toxicol. 1999;13:85–91. [PubMed] [Google Scholar] 17. Millicovsky G, Johnston MC. Maternal hyperoxia greatly reduces the incidence of phenytoin‐induced cleft‐lip and palate in A‐J mice. Science. 1981;212:671–2. [PubMed] [Google Scholar] 18. Abela D, Howe AM, Oakes DA, Webster WS. Maternal antioxidant supplementation does not reduce the incidence of phenytoin‐induced cleft lip and related malformations in rats. Birth Defects Res Part B. 2005;74:201–6. [PubMed] [Google Scholar] 19. Harbison RD, Becker BA. Diphenylhydantoin teratogenicity in rats. Toxicol Appl Pharmacol. 1972;22:193–200. [PubMed] [Google Scholar] 20. Nilsson MF, Ritchie H, Webster WS. The effect on rat embryonic heart rate of Na+, K+, and Ca2+ channel blockers, and the human teratogen phenytoin, changes with gestational age. Birth Defects Res B Dev Reprod Toxicol. 2013;98:416–27. [PubMed] [Google Scholar] 21. Moffat A, Osselton M, Widdop B. Clarke’s analysis of drugs and poisons. London: Pharmaceutical Press; 2004. [Google Scholar] 22. Hanson JW. Teratogen update: fetal hydantoin effects. Teratology. 1986;33:349–53. [PubMed] [Google Scholar] 23. Dansky LV, Finnell RH. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiologic and experimental findings spanning three decades; 2: Human studies. Reprod Toxicol. 1991;5:301–35. [PubMed] [Google Scholar] 24. Danielson MK, Danielsson B, Marchner H, Lundin M, Rundqvist E, Reiland S. Histopathological and hemodynamic studies supporting hypoxia and vascular disruption as explanation to phenytoin teratogenicity. Teratology. 1992;46:485–97. [PubMed] [Google Scholar] 25. Finnell RH, Dansky LV. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiologic and experimental findings spanning three decades; 1: Animal studies. Reprod Toxicol. 1991;5:281–99. [PubMed] [Google Scholar] 26. Azarbayjani F, Borg LA, Danielsson BR. Increased susceptibility to phenytoin teratogenicity: excessive generation of reactive oxygen species or impaired antioxidant defense? Basic Clin Pharmacol Toxicol. 2006;99:305–11. [PubMed] [Google Scholar] 27. Juchau M. Enzymatic bioactivation and inactivation of chemical teratogens and transplacental carcinogens/mutagens In: The Biochemical Basis of Chemical Teratogenesis. Juchau M. (ed). Elsevier: New York; 1981: pp. 63–94. [Google Scholar] 28. Millicovsky G, Johnston MC. Hyperoxia and hypoxia in pregnancy ‐ simple experimental manipulation alters the incidence of cleft‐lip and palate in CL‐FR mice. Proc Natl Acad Sci U S A. 1981;78:5722–3. [PMC free article] [PubMed] [Google Scholar] 29. Danielsson B, Danielson M, Rundqvist E, Reiland S. Identical phalangeal defects induced by phenytoin and nifedipine suggest fetal hypoxia and vascular disruption behind phenytoin teratogenicity. Teratology. 1992;45:247–58. [PubMed] [Google Scholar] 30. Navarova J, Ujhazy E, Dubovicky M, Mach M. Phenytoin induced oxidative stress in pre‐ and postnatal rat development ‐ Effect of vitamin E on selective biochemical variables. Biomed Pap (Olomouc). 2005;149:325–8. [PubMed] [Google Scholar] 31. Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH. Effect of diphenylhydantoin on insulin secretion in man. N Engl J Med. 1972;286:339–42. [PubMed] [Google Scholar] 32. Nabe K, Fujimoto S, Shimodahira M, Kominato R, Nishi Y, Funakoshi S, et al. Diphenylhydantoin suppresses glucose‐induced insulin release by decreasing cytoplasmic H+ concentration in pancreatic islets. Endocrinology. 2006;147:2717–27. [PubMed] [Google Scholar] 33. Salazar Garcia M, Reyes Maldonado E, Revilla Monsalve MC, Villavicencio Guzmán L, Reyes López A, Sánchez‐Gómez C. Importance of maternal diabetes on the chronological deregulation of the intrauterine development: an experimental study in rat. J Diabetes Res. 2015;2015:354265–354265. [PMC free article] [PubMed] [Google Scholar] 34. Gabbay‐Benziv R, Reece EA, Wang F, Yang P. Birth defects in pregestational diabetes: defect range, glycemic threshold and pathogenesis. World J Diabetes. 2015;6:481–8. [PMC free article] [PubMed] [Google Scholar] 35. Reece EA, Wiznitzer A, Homko CJ, Hagay Z, Wu YK. Synchronization of the factors critical for diabetic teratogenesis: an in vitro model. Am J Obstet Gynecol. 1996;174:1284–8. [PubMed] [Google Scholar] 36. Baack ML, Wang C, Hu S, Segar JL, Norris AW. Hyperglycemia induces embryopathy, even in the absence of systemic maternal diabetes: an in vivo test of the fuel mediated teratogenesis hypothesis. Reprod Toxicol. 2014;46:129‐36. [PMC free article] [PubMed] [Google Scholar] 37. Wang F, Reece EA, Yang P. Oxidative stress is responsible for maternal diabetes‐impaired transforming growth factor beta signaling in the developing mouse heart. Am J Obstet Gynecol. 2015;212:650.e1‐11. [PMC free article] [PubMed] [Google Scholar] 38. Sadler TW, Hunter ES 3rd, Wynn RE, Phillips LS. Evidence for multifactorial origin of diabetes‐induced embryopathies. Diabetes. 1989;38:70‐4. [PubMed] [Google Scholar] 39. Li R, Chase M, Jung S‐K, Smith PJ, Loeken MR. Hypoxic stress in diabetic pregnancy contributes to impaired embryo gene expression and defective development by inducing oxidative stress. Am J Physiol Endocrinol Metab. 2005;289:E591‐E599. [PubMed] [Google Scholar] 40. Singh DK, Winocour P, Farrington K. Mechanisms of disease: the hypoxic tubular hypothesis of diabetic nephropathy. Nat Clin Pract Nephrol. 2008;4:216‐26. [PubMed] [Google Scholar] 41. Nyengaard JR, Ido Y, Kilo C, Williamson JR. Interactions between hyperglycemia and hypoxia: implications for diabetic retinopathy. Diabetes. 2004;53:2931–8. [PubMed] [Google Scholar] 42. Piddington R, Herold R, Goldman AS. Further evidence for a role of arachidonic‐acid in glucocorticoid teratogenic action in the palate. Proc Soc Exp Biol Med. 1983;174:336–42. [PubMed] [Google Scholar] 43. Melnick M, Jaskoll T, Slavkin HC, Opitz JM. Corticosteroid‐induced cleft lip in mice: a teratologic, topographic, and histologic investigation. Am J Med Genet. 1981;10:333–50. [PubMed] [Google Scholar] 44. Goldman AS, Baker L, Piddington R, Marx B, Herold R, Egler J. Hyperglycemia‐induced teratogenesis is mediated by a functional deficiency of arachidonic‐acid. Proc Natl Acad Sci USA. 1985;82:8227–31. [PMC free article] [PubMed] [Google Scholar] 45. Hwang JL, Weiss RE. Steroid‐induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev. 2014;30:96–102. [PMC free article] [PubMed] [Google Scholar] 46. Hendrickx AG, Pellegrini M, Tarara R, Parker R, Silverman S, Steffek AJ. Craniofacial and central nervous system malformations induced by triamcinolone acetonide in nonhuman primates: I. General teratogenicity. Teratology. 1980;22:103–14. [PubMed] [Google Scholar] 47. Abbott BD. Review of the interaction between TCDD and glucocorticoids in embryonic palate. Toxicology. 1995;105:365–73. [PubMed] [Google Scholar] 48. Goldman AS. Biochemical mechanism of glucocorticoid‐and phenytoin‐induced cleft palate. Curr Top Dev Biol. 1984;19:217–39. [PubMed] [Google Scholar] 49. Katsumata M, Gupta C, Goldman AS. Glucocorticoid receptor IB: mediator of anti‐inflammatory and teratogenic functions of both glucocorticoids and phenytoin. Arch Biochem Biophys. 1985;243:385–95. [PubMed] [Google Scholar] 50. Tzortzatou GG, Goldman AS, Boutwell WC. Evidence for a role of arachidonic acid in glucocorticoid‐induced cleft palate in rats. Proc Soc Exp Biol Med. 1981;166:321–4. [PubMed] [Google Scholar] 51. Goldman AS, Van Dyke DC, Gupta C, Katsumata M, Opitz JM, Reynolds JF. Elevated glucocorticoid receptor levels in lymphocytes of children with the fetal hydantoin syndrome (FHS). Am J Med Genet. 1987;28:607–18. [PubMed] [Google Scholar] 52. Katsumatal M, Baker MK, Goldman AS, Gasser DL. Influence of H‐2‐linked genes on glucocorticoid receptors in the fetal mouse palate. Immunogenetics. 1981;13:319–25. [PubMed] [Google Scholar] 53. Symons D, Moxham BJ. Ultrastructural characterization of the mesenchyme of the facial processes during development of the rat intermaxillary segment. Connect Tissue Res. 2002;43:238–44. [PubMed] [Google Scholar] Page 2The effect of supplemental oxygen on the teratogenicity of phenytoin (180 mg/kg) administered to GD 11 pregnant rats
|
What can phenytoin do to a fetus?
Postagens relacionadas
direito autoral © 2024 cemle Inc.
